Gene therapy is an experimental technique that encompasses the replacement of mutated genes with healthy genes. Gene therapy is considered to be an effective treatment for chronic diseases as they cause minimum side effects with maximum efficacy and may help in an eradication of disease at a root cause level.
It’s an experimental technique that uses genes from another source to treat or prevent any type of genetic disorder. The rise in prevalence of cancer, benefits of cancer gene therapy over conventional cancer therapies, rising awareness among developing nations, approval of gene therapy products in developed nations like Europe and the advancement in this field are the major factors that are driving the market growth.
The growing popularity of the gene therapy market can be correlated with increasing number of clinical trials due to rising incidence of various types of skin disease, rise in funding for R&D activities, increase in awareness, and investment from government bodies. Over the year’s ethical acceptance of gene therapy especially with respect to the cancer treatment has grown which is further fueling the growth of gene therapy market. Moreover, rise in biotechnological funding, initiatives taken by government bodies to encourage R&D activities are also other factors driving the gene therapy market. However high costs associated with the treatment, unwanted immune response, pitfall in current technologies, stringent laws and safety and challenges in commercialization of gene therapy market are restraining the market growth.
The overall global gene therapy market is expected to witness a significant growth as it may reach approximately US$2543 million by the end of the year 2026. Several bioengineers, professionals are focusing to develop and support gene therapies with improved efficacy and safety and are aiming more towards advanced platforms for the engineering of vectors. It has also led to discovery of many novel molecular targets which has further enhanced and strengthened the research and product pipeline. Hence, the diverse product pipeline is driving factor for the growth of gene therapy market. The overall gene therapy market is segmented based on therapy area where cancer is dominating the market. Based on geographic area US is holding the major market share among Europe, Asia, Australasia.
The various key players that are playing the lead role in the gene therapy market are Pfizer, Celegene, Spark Therapeutics, GlaxoSmithKline, Blubirdbio Therapeutics, Sanofi, Uniqure, Orchard Therapeutics, Abeona Therapeutics, OxfordBiomedica. Glybera, the first gene therapy product which is used for the treatment of lipoprotein lipase deficiency is the product of Uniqure and has been given an orphan drug status in the European Union as well as the US. Strimvelis, another gene therapy product developed by GlaxoSmithKline which proved to be successful against ADA-SCID (Severe Combined Immune Deficiency). SPK9001 is an another breakthrough product against Hemophilia B was developed by Spark and Pfizer, which involves a bioengineered gene designed to prompt the body to produce increased levels of a different clotting factors.
The report provides an extensive study on the current market landscape of gene therapies by therapy area, by regions, by vectors and by key players, featuring an elaborate discussion on the future potential of this evolving market.
Key questions answered
- Global Gene Therapy Market by Value; 2014-2026
- Global Gene Therapy Market Share by Therapy Area; 2015
- Global Gene Therapy Market Share by Vectors; 2015
- Global Gene Therapy Clinical Trials by Therapy Areas; 2017
- Global Gene Therapy Market Share by Regions; 2018
- Global Gene Therapy Market by M&A Deals; 2017
- US Gene Therapy Market by Value; 2013-2026
- US Gene Therapy Share by Therapy Area; 2013-2026
- US Hematology Gene Therapy Market by Value; 2013-2026
- US Oncology Gene Therapy Market by Value; 2013-2026
- US Infectious disease Gene Therapy Market by Value; 2013-2026
- US Muscular Disease Gene Therapy Market by Value; 2013-2026
- Europe Gene Therapy Market by Value; 2014-2026
- Europe Gene Therapy Market Share by Sector; 2014-2026
- Europe Gene Therapy Market by Companies; 2014-2026
- Europe Gene Therapy Market by Academic and Government Research Institutions; 2014-2026
- Europe Gene Therapy Market by Contract and Research Institutions; 2014-2026
- Asia Gene Therapy Market by Value; 2014-2026
- Australasia Gene Therapy Market by Value; 2014-2026
- Number of Approved Gene Therapy Trials Worldwide; 1989-2015
- Patent Landscape
- Growth drivers, future opportunities and challenges in the market
- Merger and Acquisition, and Collaboration of Key Players
- Detailed company profiling of key market players
1. Executive Summary
2. Gene Therapy: Overview
I. Viral Vectors for Gene Therapy
a. Viral Vectors
b. Non-Viral Vectors
II. Types of Gene Therapy
a. Somatic Gene Therapy
b. Germ Line Gene Therapy
III. Approaches to Gene Therapy
a. Gene Therapy Strategies
b. Gene Augmentation Therapy
c. Targeted Killing of Specific Cells
d. Targeted Inhibition of Gene Expression
e. Targeted Gene Mutation Correction
IV. Gene Therapy Methods
a. Ex Vivo Gene Therapy
b. In Vivo Gene Therapy
V. Advantages and Disadvantages of Gene Therapy
a. Advantages
b. Disadvantages
VI. Major Applications of Gene Therapy
3. Gene Therapy Market Outlook and Forecast
I. Global Gene Therapy Market: An Analysis
II. Global Gene Therapy Market by Value
III. Global Gene Therapy Market by Therapy Area
IV. Global Gene Therapy Market by Vector type
V. Global Gene Therapy Market by Clinical Trials
VI. Global Gene Therapy Market by Regions
VII. US Gene Therapy Market: An Analysis
a. US Gene Therapy Market by Therapy Area
VIII. Europe Gene Therapy Market: An Analysis
IX. Asia Gene Therapy Market
4. Patent Landscape
I. Gene Therapy Patent Trend by Focus Area
II. Gene Therapy Patent Trend by Gene Transfer Method
III. Gene Therapy Patent Trend by Therapy Techniques
IV. Gene Therapy Patent Trend by Applications
V. Key Patents in the domain
VI. Gene Therapy Patents by Key Players
VII. Gene Therapy Patents by Key Inventors
5. Market Dynamics
I. Growth Drivers
a. Failure of Conventional Therapies to Treat Cancer
b. Enhance Gene Therapy Awareness Among Developed Nations
c. Approvals of Gene Therapy Drug in Europe
d. Gene Therapy for Hemophilia B and Inherited Blindness
II. Trends
a. Gene Silencing
b. Combining Stem Cell Technology & Gene Therapy
c. Empowering Gene therapy: Nanotechnology
d. Stringent Laws and Safety Concerns
III. Challenges in Commercialization of Gene Therapy
a. High Cost of Gene Therapy Drugs
b. Pitfall in Current Technologies
6. Mergers and Acquisitions
7. Competitive Landscape
8. Company Profiles
I. Pfizer
a. Business Overview
b. Financial Overview
c. Product Overview
II. Celgene
a. Business Overview
b. Financial Overview
c. Product Overview
III. Spark Therapeutics
a. Business Overview
b. Financial Overview
c. Product Overview
IV. GlaxoSmithKline
a. Business Overview
b. Financial Overview
c. Product Overview
V. Blubirdbio Therapeutics
a. Business Overview
b. Financial Overview
c. Product Overview
VI. Sanofi
a. Business Overview
b. Financial Overview
c. Product Overview
VII. Uniqure
a. Business Overview
c. Product Overview
VIII. Orchard Therapeutics
a. Business Overview
b. Financial Overview
c. Product Overview
IX. Abeona Therapeutics
a. Business Overview
b. Financial Overview
c. Product Overview
X. Oxford Biomedica
a. Business Overview
b. Financial Overview
c. Product Overview
9. About EffeMarket
10. Disclaimer
11. Contact US
Figure 1: Genetic Makeup of an Organism
Figure 2: General DNA Cloning using Vector System
Figure 3: Vectors Used in Gene Therapy
Figure 4: Adenoviral Vector: Mechanism of action
Figure 5: Retroviral Vector: Mechanism of Action
Figure 6: Direct Injection/Microinjection
Figure 7: Particle Bombardment Method of Gene Transfer
Figure 8: Liposome Mediated Gene Transfer
Figure 9: Electroporation Method of Gene Transfer
Figure 10: Different Classes of Gene Therapy
Figure 11: Gene Therapy Approaches
Figure 12: Different Strategies of Gene Therapy
Figure 13: Gene Augmentation Therapy
Figure 14: Targeted Killing of Specific Cells
Figure 15: Targeted inhibition of Gene Expression
Figure 16: Targeted Gene Mutation Correction
Figure 17: Gene Therapy Methods
Figure 18: Ex Vivo Gene Therapy
Figure 19: In Vivo Gene Therapy
Figure 20: Global Gene Therapy Market by Value; 2014-2026
Figure 21: Global Gene Therapy Market Share by Therapy Area; 2015
Figure 22: Global Gene Therapy Market Share by Vector Type; 2015
Figure 23: Global Gene Therapy Market Share by Vector Type; 2015
Figure 24: Global Gene Therapy Clinical Trials by Therapy Areas; 2017
Figure 25: Global Gene Therapy Market Share by Regions; 2018
Figure 26: Global Gene Therapy Market by M&A Deals; 2017
Figure 27: US Gene Therapy Market by Value; 2013-2026
Figure 28: US Hematology Gene Therapy Market by Value; 2013-2026
Figure 29: US Oncology Gene Therapy Market by Value; 2013-2026
Figure 30: US Infectious disease Gene Therapy Market by Value; 2013-2026
Figure 31: US Muscular Disease Gene Therapy Market by Value; 2013-2026
Figure 32: Europe Gene Therapy Market by Value; 2014-2026
Figure 33: Europe Gene Therapy Market Share by Sector; 2014-2026
Figure 34: Europe Gene Therapy Market by Companies; 2014-2026
Figure 35: Europe Gene Therapy Market by Academic and Government Research Institutions; 2014-2026
Figure 36: Europe Gene Therapy Market by Contract and Research Institutions; 2014-2026
Figure 37: Asia Gene Therapy Market by Value; 2014-2026
Figure 38: Australasia Gene Therapy Market by Value; 2014-2026
Figure 39: Overall IP Trends in Gene Therapy; 1988-2018
Figure 40: Earliest Priority Country Filing Trend in Gene Therapy; 1988-2018
Figure 41: Gene Therapy Patent Trend by Focus Area; 1988-2018
Figure 42: Gene Therapy Patent Trend by Focus Area; 1988-2018
Figure 43: Gene Therapy Patent Trend by Viral & Non-Viral Vector; 1988-2018
Figure 44: Gene Therapy Patent Trend by Viral Vector; 1988-2018
Figure 45: Gene Therapy Patent Trend by Non-Viral Vector; 1988-2018
Figure 46: Gene Therapy Patent Trend by Therapy Techniques; 1988-2018
Figure 47: Gene Therapy Patent Trend by Therapy Techniques; 1988-2018
Figure 48: Gene Therapy Patent Trend by Key Patent Holders (Legal Assignees); 1988-2018
Figure 49: Gene Therapy Patent Trend by Top Inventors in the domain
Figure 50: CAR-T Cell Therapy
Figure 51: Number of Patent Applications in China
Figure 52: Total Patent Applications; 2017
Figure 53: Types of Gene Silencing
Figure 54: Gene Silencing Mechanism
Figure 55: Research Papers and Citations in Gene Silencing Area; 2002-2003
Figure 56: Principles for the Governance of Gene Editing
Figure 57: Number of Approved Gene Therapy Trials Worldwide; 1989-2015
Figure 58: Prices of Gene Therapy Products
Figure 59: Pfizer Revenue; 2013-2017
Figure 60: Celgene Revenue; 2013-2017
Figure 61: Celgene R&D Expenses; 2015-2017
Figure 62: Spark Therapeutics Revenue; 2013-2017
Figure 63: Spark Therapeutics R&D Expenses; 2013-2017
Figure 64: GlaxoSmithKline Revenue; 2015-2017
Figure 65: GlaxoSmithKline R&D Expenses; 2015-2017
Figure 66: Blubirdbio Revenue; 2013-2017
Figure 67: Blubirdbio R&D Expenses ;2013-2017
Figure 68: Sanofi Revenue; 2013-2017
Figure 69: Uniqure Revenue; 2013-2017
Figure 70: Uniqure R&D Expenses;2013-2017
Figure 71: Orchard Therapeutics Total Capital Raised
Figure 72: Abeona Revenue; 2013-2017
Figure 73: Abeona R&D Expenses; 2013-2017
Figure 74: Oxford Biomedica Revenue; 2013-2017
Figure 75: Oxford BiomedicaR&D Expenses; 2013-2017
Table 1: Viral and Non-Viral Gene Transfer Methods
Table 3: Gene Therapy Products Approved by European Medicine Agency
Table 4: Gene Therapy Patent Trend by Focus Area (Year Wise Filing); 2007-2018
Table 5: Gene Therapy Patent Trend by Gene Transfer Method (Year Wise Filing); 2007-2018
Table 6: Gene Therapy Patent Trend by Applications; 2007-2018
Table 7: Key Patents in the domain
Table 8: Key Players Year Wise Patent Publication;2007-2018
Table 9: Key Players Year role in patent focus
Table 10: Key Players Year role in Gene transfer Method
Table 11: Key Players role in Applications
Table 12: Key Players Collaboration
Table 13: Top Inventors actively associated with the key players
Table 14: Top Inventors Gene Therapy for Hemophilia B
Table 15: Competitive Landscape
Table 16: Major Pharma Collaborations for Gene Strategy Implementation
Table 17: Spark Therapeutics Product Pipeline
Table 18: Blubirdbio Therapeutics Product Pipeline
Table 19: Sanofi Product Pipeline
Table 20: Uniqure Product Pipeline
Table 21: Orchard Therapeutics Product Pipeline
Table 22: Abeona Therapeutics Product Pipeline
Table 23: OxfordBiomedica Product Pipeline
-Market-Report-2024.jpg)
